MedTrace Logo

Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer

NCT02312661 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-05-06

No results posted yet for this study

Summary

Molecularly targeted agents which inhibit the mammalian target of rapamycin (mTOR) pathway and/or circumvent p53 in the induction of apoptosis are exciting potential targets in ovarian cancer. Metformin is a biguanide, widely used in the treatment of type 2 diabetes mellitus, that has shown anti-cancer activity in preclinical studies. The main mechanism of metformin's effect is mTOR pathway inhibition and, in addition, it has been shown to circumvent p53-induced apoptosis making it an exciting, potentially effective drug in ovarian cancer.

Conditions

  • Epithelial Ovarian Cancer

Interventions

DRUG

Metformin

Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy

DRUG

Carboplatin

Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles

DRUG

Paclitaxel

Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-05
Primary Completion
2017-11-30
Completion
2017-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02312661 on ClinicalTrials.gov